Sona Saksena1, Rajan Jain1,
Jayant Narang1, Lonni Schultz2, David Hearshen1,
Lisa Scarpace3, Norman Lehman4, Tom Mikkelsen3
1Radiology, Henry Ford Hospital,
Detroit, MI, United States; 2Biostatistics and Research
Epidemiology, Henry Ford Hospital, Detroit, MI, United States; 3Neurosurgery,
Henry Ford Hospital, Detroit, MI, United States; 4Pathology, Henry
Ford Hospital, Detroit, MI, United States
DTI
data were acquired from thirty-four patients with glioblastomas with an aim
to retrospectively correlate the changes in fractional anisotropy (FA) and
apparent diffusion coefficient (ADC) with degree of proliferation index
determined histologically and patient survival analysis. We found that
patients with ADCmin (0.6) and FAmean (0.2) had lower progression free
survival rate or poorer prognosis. In conclusion, DTI can be used as a
clinical prognostic biomarker for disease free survival in patients with
glioblastomas and might be useful for planning initial treatment strategy in
these patients.